Compositions and methods for silencing genes involved in hemorrhagic fever
US8455455B1 · kind B1 · utility
19Cited by
25References
30Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 31, 2011 |
| Grant date | Jun 4, 2013 |
| Priority date | — |
| Expiry date | Jun 17, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target Lassa virus (LASV) or tissue factor (TF) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating hemorraghic fever).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.